Oryzon Genomics Balance Sheet Health
Financial Health criteria checks 3/6
Oryzon Genomics has a total shareholder equity of $92.7M and total debt of $19.3M, which brings its debt-to-equity ratio to 20.8%. Its total assets and total liabilities are $118.6M and $25.9M respectively.
Key information
20.8%
Debt to equity ratio
US$19.27m
Debt
| Interest coverage ratio | n/a |
| Cash | US$10.79m |
| Equity | US$92.68m |
| Total liabilities | US$25.88m |
| Total assets | US$118.56m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RDB's short term assets ($14.9M) do not cover its short term liabilities ($15.7M).
Long Term Liabilities: 0RDB's short term assets ($14.9M) exceed its long term liabilities ($10.2M).
Debt to Equity History and Analysis
Debt Level: 0RDB's net debt to equity ratio (9.1%) is considered satisfactory.
Reducing Debt: 0RDB's debt to equity ratio has reduced from 33% to 20.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0RDB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 0RDB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6.8% each year